On February 11, 2022, the US Food and Drug Administration approved the COVID-19 monoclonal antibody (mAb) treatment called bebtelovimab made by Eli Lilly and Co., making it available for emergency use.
This fact sheet contains information about the bebtelovimab treatment to help you make informed decisions about treatments for COVID-19 that may help reduce your risk of severe illness.
Disclaimer: as of November 30, 2022, the U.S. Food and Drug Administration has revoked approval of the COVID-19 monoclonal antibody (mAb) treatment called bebtelovimab in all U.S. states and territories. This is due to an increase in COVID-19 cases caused by the Omicron BQ.1 and BQ.1.1 sub-variants and data showing that bebtelovimab is unlikely to be as effective against them.